Phase 2a RCT in South Africa (694 adults; 588 with HIV in primary analysis): a single boost of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN raised antibodies by day 15 (neutralising GMFC 2.6, 10.0 and 4.5). Reactions were mostly mild; no safety issues.
RCTn = 694
Govender et al. Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial